drug · antibody
barzolvolimab
Phase 3updated 3mo agoby $CLDX Celldex Therapeutics, Inc.🔗 ChEMBL
Phase 3community read0 votes
Antibody drug with a maximum clinical stage of Phase 3 (across all indications), with 3 investigational indications.
all catalysts(0)
nothing on the calendar yet
Trials studying barzolvolimab
- phase2A Study of Barzolvolimab in Patients With Prurigo Nodularis
- phase3A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
- phase3Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
- phase2A Study of Barzolvolimab in Patients With Atopic Dermatitis
- phase3A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
- phase3A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
- phase2A Study of CDX-0159 in Patients With Eosinophilic Esophagitis
- phase2A Study of CDX-0159 in Patients With Chronic Inducible Urticaria
News(4)
- STAT+: Pharma tries to tamp down broad China restrictionsAI-focused VC firm raises $800M, Merck's new cholesterol pill, and more biotech news from The Readoutstat · 20d ago
- Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease studyA new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck debuted data for a once-weekly HIV tablet and a new pyschedelics competi…biopharma_dive · 20d ago
- Celldex ends skin disease program after failing phase 2 testA phase 2 study of Celldex’s barzolvolimab in a chronic skin disease has missed its primary endpoint, driving the biotech to end development in the indication and raising doubts about an upcoming e…fiercebiotech · 20d ago
- 10 clinical trials to watch in the second half of 2026The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.biopharma_dive · 1mo ago
Data sources
last refreshed 31m ago
Found something off?
comments(0)
5-min edit window · permanent after that